30S ribosomal subunit Inhibitors
1 drugsAbout 30S ribosomal subunit
The 30S ribosomal subunit is a crucial component of bacterial ribosomes, responsible for protein synthesis. Targeting this subunit disrupts bacterial growth and proliferation by inhibiting protein production.
The 30S ribosomal subunit is a target for antibacterial drug development. Currently, there is no genetic evidence available directly linking variations in the 30S ribosomal subunit to specific diseases.
One FDA-approved drug, DOXY 100 (Fresenius Kabi), targets the 30S ribosomal subunit. This drug is a small molecule with 9 indications, classified under the therapeutic area 'Other'.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Carcinoma, Non-Small-Cell Lung with only 1 trials.
Top 30S ribosomal subunit Drugs
Fresenius Kabi is the top company with an approved drug targeting the 30S ribosomal subunit.
The market is highly concentrated, suggesting high barriers to entry or limited commercial opportunity.
30S ribosomal subunit Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 30S ribosomal subunit, using small molecule modality.
Explore alternative modalities like oligonucleotides or peptides to differentiate from existing drugs.
30S ribosomal subunit Clinical Trials 117 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 5 | 3 | 2 | 63% |
| Phase 2 | 41 | 23 | 7 | 11 | 77% |
| Phase 3 | 18 | 15 | 2 | 1 | 88% |
| Phase 4 | 48 | 33 | 5 | 9 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
30S ribosomal subunit Drug Approval Timeline (1983 - 1983)
The first and most recent drug approval for this target was DOXY 100 in 1983.
The lack of recent approvals indicates a saturated market or challenges in developing new drugs for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 81 clinical trials targeting 30S ribosomal subunit.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities